tiprankstipranks
ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ:ACAD
US Market
ACAD
ACADIA Pharmaceuticals
RESEARCH TOOLSreports
Want to see ACAD full AI Analyst Report?

ACADIA Pharmaceuticals (ACAD) Stock News & Sentiment

2,439 Followers
ACADIA Pharmaceuticals Signals Confident Path After Q1 Call
Premium
Company Announcements
ACADIA Pharmaceuticals Signals Confident Path After Q1 Call
17d ago
ACAD
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained
Premium
Ratings
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained
17d ago
ACAD
ACADIA: Buy Rating Reiterated on Nuplazid/Daybue Upside and Remlifanserin Optionality; $32 DCF-Based Price Target Maintained
Premium
Ratings
ACADIA: Buy Rating Reiterated on Nuplazid/Daybue Upside and Remlifanserin Optionality; $32 DCF-Based Price Target Maintained
17d ago
ACAD
Is ACAD a Buy, Before Earnings?
Premium
Pre-Earnings
Is ACAD a Buy, Before Earnings?
21d ago
ACAD
Acadia Announces Planned Retirement of Head of R&D
Premium
Company Announcements
Acadia Announces Planned Retirement of Head of R&D
23d ago
8K
ACAD
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
Premium
Company Announcements
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
3M ago
8K
ACAD
Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
Premium
Ratings
Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
3M ago
ACAD
More ACAD News >

ACAD News on the Web

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF), ACADIA Pharmaceuticals (ACAD) and Immunic (IMUX)
TipRanks News
Neutral
ACADIA Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
GuruFocus News
Neutral
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth
MarketBeat
Bullish
Baker Bros. Advisors LP Increases Stake in Incyte Corp with Strategic Acquisition
GuruFocus News
Neutral
Why ACADIA Pharmaceuticals Stock Is Surging Today
TipRanks News
Bullish
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
MarketBeat
Bullish
BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
TipRanks News
Bullish
Guggenheim Keeps Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
ACAD
Sector Average
Media Buzz
This Week3 articles
Weekly Average6.75 articles
News Sentiment
This Week99%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ACAD’s Media Buzz Sentiment?
3 articles about ACAD were published this week. In an average week, 6.75 articles are published.
    What is ACAD’s weekly average amount of articles?
    In an average week, 6.75 articles about ACAD are published.
      What is ACAD’s News Sentiment?
      99% of articles about ACAD were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        TLSATiziana Life Sciences
        Showing the stocks with the most bullish news sentiment over the past week